在非中性衰竭患者的肝炎候群病中
Maria Carolina Carvalho1, Matilde Coimbra1, Micaela Caixeiro2
1Department of Internal Medicine IV, Hospital Prof. Dr. Fernando Fonseca, Amadora, PRT.
Cureus
|February 9, 2026
概括
严重的侵入性真菌感染,肝炎候群病,可以发生在非中性贫症患者. 早期诊断和及时的抗真菌治疗对于管理这种具有挑战性的疾病和预防复发至关重要.
科学领域:
- 菌类学 菌类学是指菌类学.
- 传染性疾病 传染性疾病
- 医疗成像医学成像
背景情况:
- 肝疹是一种罕见但严重的侵入性疹 (IC) 形式.
- 通常与血液恶性瘤或腹部外科手术后的中性衰竭有关.
- 由于培养物敏感性低,血清学检测极限和活检不切实际,诊断很困难.
研究的目的:
- 为了突出肝癌的诊断复杂性.
- 强调非中性衰竭患者临床怀疑的重要性.
- 讨论管理策略和成像在IC中的作用.
主要方法:
- 在非中性衰竭患者中肝炎候群的病例呈现.
- 对诊断挑战的审查,包括CT和18FDG-PET等成像模式.
- 基于专家意见和回顾性数据,讨论当前的管理.
主要成果:
- 肝炎候群病可以在具有危险因素的非中性衰竭个体中呈现.
- 图像 (CT,18FDG-PET) 对于诊断和监测治疗反应至关重要.
- 及时的抗真菌治疗和长期治疗是预防复发的必要条件.
结论:
- 保持对肝癌的临床怀疑是必不可少的,即使在非中性衰竭患者中也是如此.
- 有效的管理包括及时的抗真菌治疗,感染源控制和放射性监测.
- 需要进一步的研究,以优化诊断,分子技术和识别遗传倾向.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System
6.1K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.1K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
248
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
248
Hepatic Drug Excretion: Influencing Factors
597
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
597
Hepatic Drug Clearance: Role of Transporters
311
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
311
Hepatic Drug Excretion: Enterohepatic Cycling
2.8K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.8K


